4 patents currently held
12 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Mar 2027. from the record
Of the 12 now held by other companies, 11 name Daiichi Sankyo Company Limited as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Mar 2027
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2029 · High confidence
Also notable
Ends Mar 2027 · High confidence
Also notable
Ends Aug 2032 · High confidence
Imidazolothiazole Compounds and Methods of Use Thereof
US 8,551,963
The most cited patent in this portfolio, cited by 28 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2029.
Imidazolothiazole Compounds for the Treatment of Disease
US 8,921,546
The largest patent family in this portfolio, 55 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Process for the Preparation of Imidazo[2,1-b][1,3]benzothiazole Derivatives
US 9,284,332
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2032.
Formerly held, still cited
Notable
Ends Mar 2027 · High confidence
Cited by 26 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Daiichi Sankyo Company, Limited
Also notable
Ends Feb 2031 · High confidence
Cited by 25 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
now held by Daiichi Sankyo Company, Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Sep 15, 2027The maintenance fee for Process for the Preparation of Imidazo[2,1-b][1,3]benzothiazole Derivatives (US 9,284,332) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Heterocyclic Compounds and Methods of Use Thereof | 2 in force | to Oct 2032 |
| Process for the Preparation of Imidazo[2,1-b][1,3]benzothiazole Derivatives | 1 in force | to Aug 2032 |
| Imidazolothiazole Compounds and Methods of Use Thereof | 1 in force | to Nov 2029 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,921,546 | Imidazolothiazole Compounds for the Treatment of Disease In force · High confidence | In force | High confidence | |
| US 8,551,963 | Imidazolothiazole Compounds and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,284,332 | Process for the Preparation of Imidazo[2,1-b][1,3]benzothiazole Derivatives In force · High confidence | In force | High confidence | |
| US 8,952,058 | Heterocyclic Compounds and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 12 patents in force now held by others · 21 patents ended · 1 application pending · 36 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.